Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

Company Overview

Daiichi Sankyo Co., Ltd. is a Japan-based pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Its business is centered on oncology, with additional operations in areas such as cardiovascular disease, immunology, and other serious medical conditions.

The company’s oncology portfolio includes antibody-drug conjugates, a technology designed to deliver potent cancer treatments more selectively to tumor cells. Daiichi Sankyo develops and commercializes medicines independently and through collaborations, including its partnership with AstraZeneca on trastuzumab deruxtecan, marketed as Enhertu, for certain cancer indications.

Daiichi Sankyo was formed in 2005 through the merger of Daiichi Pharmaceutical and Sankyo. The company traces its corporate roots to Japanese pharmaceutical businesses established in the late 19th and early 20th centuries. Headquartered in Tokyo, Daiichi Sankyo serves patients and healthcare providers in Japan and international markets through research, manufacturing, regulatory, and commercial operations.

Key Stats

• Today's Range: $16.86 to $17.48
• 50-Day Range: $16.00 to $19.00
• 52-Week Range: $14.98 to $27.50
• Volume: 100,787 shs
• Average Volume: 98,584 shs
• Market Capitalization: $32.32 billion
• P/E Ratio: 20.17
• Dividend Yield: 1.96%
• Price Target: N/A
• Consensus Rating: Hold

Daiichi Sankyo Stock Analysis - MarketRank™

Daiichi Sankyo scored higher than 68% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Daiichi Sankyo has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Daiichi Sankyo has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 16.13%

Earnings Growth

Earnings for Daiichi Sankyo are expected to grow by 16.13% in the coming year, from $0.93 to $1.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Daiichi Sankyo is 20.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Daiichi Sankyo is 20.17, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.32.

Price to Earnings Growth Ratio

Daiichi Sankyo has a PEG Ratio of 1.86. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Daiichi Sankyo has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Daiichi Sankyo has been sold short.

Short Interest Ratio / Days to Cover

Daiichi Sankyo has a short interest ratio ("days to cover") of 0.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daiichi Sankyo has recently decreased by 15.28%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Daiichi Sankyo pays a meaningful dividend of 1.98%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Daiichi Sankyo does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Daiichi Sankyo is 39.53%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Daiichi Sankyo will have a dividend payout ratio of 31.48% next year. This indicates that Daiichi Sankyo will be able to sustain or increase its dividend.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for DSNKY on MarketBeat in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Daiichi Sankyo insiders have not sold or bought any company stock.

Percentage Held by Institutions

Daiichi Sankyo has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 10/05/2026
• Next Earnings (Estimated): 10/30/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:DSNKY
• Previous Symbol: OTCMKTS:DSNKY
• CIK: N/A
• Web: www.daiichisankyo.com
• Phone: (136) 225-1111
• Fax: N/A
• Employees: 20,171
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): $0.86
• Trailing P/E Ratio: 20.17
• Forward P/E Ratio: 18.66
• P/E Growth: 1.86
• Net Income: $1.72 billion
• Net Margins: 10.92%
• Pretax Margin: 12.41%
• Return on Equity: 14.35%
• Return on Assets: 6.10%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 2.92
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: $14.10 billion
• Price / Sales: 2.29
• Cash Flow: $1.18 per share
• Price / Cash Flow: 14.71
• Book Value: $5.80 per share
• Price / Book: 2.99

Miscellaneous

• Outstanding Shares: 1,862,893,000
• Free Float: N/A
• Market Cap: $32.32 billion
• Optionable: Not Optionable
• Beta: -0.11